Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.

Cancer gene therapy - 1 Oct 2016

Somnay Y, Lubner S, Gill H, Matsumura J B, Chen H

Abstract excerpt

Monoagent DNA-alkylating chemotherapies like dacarbazine are among a paucity of medical treatments for advanced carcinoid tumors, but are limited by host toxicity and intrinsic chemoresistance through the base excision repair (BER) pathway via poly (ADP-ribose) polymerase (PARP). Hence, inhibitors of PARP may potentiate DNA-damaging agents by blocking BER and DNA restoration. We show that the PARP inhibitor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Carcinoid Tumor
Share to Cell Death

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase Inhibitor p21

Share to Dacarbazine

Share to Drug Synergism

Share to Neoplasm Metastasis

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 27632933
DOI: 10.1038/cgt.2016.39
PMCID: PMC5083201

Genes

ASCL1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.PMID 27632933Read ↗

Advancing cancer therapy: new frontiers in targeting DNA damage responseSemantic proximity Read ↗

Enhancing the anti-tumor response by combining DNA damage repair inhibitors in the treatment of solid tumorsSemantic proximity Read ↗

Enhancing PDAC Therapy: Decitabine-Olaparib Synergy Targets KRAS-Dependent TumorsSemantic proximity Read ↗

Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging AgentsSemantic proximity Read ↗

DNA Damage Repair Inhibitors-Combination Therapies.Semantic proximity Read ↗

The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma EffectsSemantic proximity Read ↗

P53 reactivator PRIMA-1 MET synergizes with 5-Fluorouracil to induce apoptosis in pancreatic tumor cellsSemantic proximity Read ↗

Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract CancerSemantic proximity Read ↗

A first-in-class inhibitor of homologous recombination DNA repair counteracts tumour growth, metastasis and therapeutic resistance in pancreatic cancerSemantic proximity Read ↗

Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract CancerSemantic proximity Read ↗

Newer Cytotoxic Agents: Attacking Cancer BroadlySemantic proximity Read ↗

Cetuximab Augments Cytotoxicity with Poly (ADP-Ribose) Polymerase Inhibition in Head and Neck CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.